Samjin Pharmaceutical Co., Ltd. Speeds Up Commercialization of New Alzheimer's Drug AR1001, Secures Exclusive Sales Rights in Korea
- Input
- 2026-11-18 15:31:25
- Updated
- 2026-11-18 15:31:25

Samjin Pharmaceutical Co., Ltd. said on the 18th that it viewed the top-line results of AR1001's global Phase 3 trial positively and would work with Aribio on follow-up development and commercialization.
Aribio had earlier presented the key results of its global Phase 3 trial, ‘POLARIS-AD,’ at the Alzheimer's disease clinical trials conference ‘CTAD 2026,’ held in Boston, United States, on the 17th.
The trial enrolled 1,535 patients with early Alzheimer's disease in 13 countries, who received either AR1001 30 mg or a placebo once daily for 52 weeks. Designed in consultation with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), the trial would meet its primary endpoint if statistical significance was achieved in either the overall patient population or the monotherapy group.
Of note were the results in the 604 patients in the monotherapy group, who did not take existing Alzheimer's disease treatments concomitantly. Worsening on the primary endpoint, the Clinical Dementia Rating–Sum of Boxes (CDR-SB), was 31% lower in the AR1001 group than in the placebo group. The difference in scores was -0.44 points, achieving statistical significance.
The AR1001 group also showed a significant 0.7-point difference from the placebo group on the secondary endpoint, the Mini-Mental State Examination (MMSE) (p=0.0232). Biomarker analysis showed a significant increase in cGMP, a signaling molecule in the brain, and a significant decrease in p-tau217, an Alzheimer's disease-related biomarker, compared with placebo (p=0.0402). The rates of serious adverse events were also similar: 10.0% in the AR1001 group and 9.8% in the placebo group.
Samjin Pharmaceutical Co., Ltd. President Kim Sang-jin, who attended the presentation, said, “I believe AR1001 has succeeded in its global Phase 3 trial,” adding, “I received congratulations and encouragement from Professor Sharon Sha, who gave the presentation, and clinicians there.” He continued, “I also agreed with the CEO of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., who attended with me, that we would work together to accelerate commercialization.”
Kim also cited the incorporation of Phase 2 results into the trial design as a key factor in the results. He explained, “We incorporated from the Phase 3 protocol design stage the finding that patients who did not take symptom-relieving drugs concomitantly had good results in Phase 2,” adding, “In consultation with the FDA and EMA, we set separate success criteria for the overall patient population and the monotherapy group, and designed the trial so that meeting the criteria in either group would fulfill the primary objective.”
Samjin Pharmaceutical Co., Ltd. plans to flesh out the approval process and commercialization preparations based on the domestic manufacturing and exclusive sales rights it has secured.
[email protected] Jung Sang-hee Reporter